Alembic Pharmaceuticals Ltd Q4 FY2024 Concall Summary

Key Takeaways

• Gross margin surged, but watch the base: Gross margin hit 75% in Q4 (72% for FY24), well above management's 70% comfort target, driven by U.S. volumes, R&D optimization and better facility occupancy.
• New facilities are the margin story: Four commercialized facilities carry ~₹300 cr in annual costs (including depreciation) while revenue from them is still very small; the path back to 20%+ operating margins runs entirely through approvals and traction from these assets.
• U.S. optimism is real but price erosion is the wildcard: Management is "fairly optimistic" and plans 25 launches in FY25, yet concedes price erosion in high-margin products is the one unknown that could mute the growth those launches should deliver.
• India business is two-speed: Specialty therapies (gynecology, cardiology, GI, ophthalmology) are outperforming the market, while oral liquids and respiratory are dragging on a high-base correction that should moderate in FY25.
• What to watch next quarter: Whether the 25 planned U.S. launches begin converting into revenue that outruns price erosion, whether the ₹300 cr facility cost burden starts to ease as products gain traction, and whether the acute-therapy base effect in India truly fades.

The Margin Bridge: Gross Strength, Operating Drag

• Gross margin beat: Q4 gross margin reached 75%, full-year 72%, both above the 70% level management calls sustainable; drivers were higher U.S. sales revenue, optimized R&D costs, other cost optimization and better facility occupancy.
• Operating margin lag: Despite strong gross margins, operating margins remain well below the historical 20%+ level the company achieved at similar gross margins, because four newly commercialized facilities impose ~₹300 cr in annual costs (including depreciation) while contributing very little revenue.
• The recovery mechanism: As more products win approval from these facilities and gain market traction, operating leverage should improve; management hopes to return to "20% plus kind of margins" but declined to give a timeline.
• Cost levers in play: Better facility utilization, higher batch sizes and improved volumes as facilities become better occupied are the primary margin levers beyond revenue growth.
• FY24 comparability caveat: FY24 EBITDA and net profit are not comparable with FY23 because FY23 capitalized new-facility expenses through December and expensed them only from January, while FY24 carried the full-year expense; nonrecurring items in FY23 add further distortion.

Raj Kumar Baheti: "Your observations are right, but you must also appreciate the fact that we have commercialized 4 new facilities and the yearly expenses on these 4 facilities are about INR300 crores, including the depreciation. So that charge is hitting my P&L, whereas the revenue from these facilities are still very small. So more products get approval and the products get traction in the market, you will see a better improvement in margin scenario."

U.S. Business: Launches, Pricing and the Base

• Q4 base established: The $51 million quarter is "regular base business," not one-time supply; Q3 had more one-time opportunities, so Q4 "could be the base, and then we build it up from there."
• Launch pipeline: 7 products launched in Q4, 3 ANDAs filed, 5 additional approvals received since April 1 (including 2 tentative); management expects to launch "another 25 or so" products in FY25, with no assured exclusivity or semi-exclusivity positions.
• Growth outlook qualified: With 25 launches, "we should see a decent growth," but the unknown variable is price erosion, especially on high-margin products; the company grew U.S. business 10% this year and is "fairly optimistic as compared to a year back."
• Price erosion reality: Management expects erosion in "high single digits or low double digits, somewhere around" that range, varying product to product; the market is much better supplied than five years ago with more players and more products, and "it is a buyer's market."
• No therapy-wise focus: Capabilities span oral solids, increasingly injectables, oncology, ophthalmic and derm; the company prioritizes "maximum margin rather than getting market share for the sake of getting market share," ramping share when shortages appear.
• Regulatory clean: All EIRs are in place for all facilities; no regulatory overhang.

Pranav Amin: "I agree with these kind of launches, we should see a decent growth, in my opinion. Having said that, the one unknown or the variable is the price erosion. I don't know how the price erosion is going to fare on some of the high-margin products."

India Branded Business: Specialty Strength, Acute Drag

• Specialty outperformance: Gynecology, gastroenterology, antidiabetic, cardiology and ophthalmology segments did "significantly well" and outperformed the market; Animal Healthcare continued robust performance driven by volume, regional expansion and an additional division added in the livestock wet business last year.
• Acute therapy base effect: Oral and respiratory baskets, especially oral liquids in antibiotics and respiratory, carried a significantly higher base from FY22 and FY23, pulling growth to almost flat or negative; the company did marginally better than the market in these segments.
• Normalization expected: Management expects the base impact to moderate out in FY24-25, making it "more towards a normal year in terms of growth," with mid- to high single-digit performance for the overall market.
• Portfolio confidence: 95% of the overall portfolio should "do pretty well and significantly outperform the market," assuming the market returns to normalcy; no manpower expansion is planned, only routine adjustments.

Shaunak Amin: "I expect this base impact of previous years to get moderated out... So I expect '24-'25 to be more towards a normal year in terms of growth."

R&D Reallocation and Capex Discipline

• R&D pivot underway: Spend is shifting from oral solids toward injectables, complex injectables, derm, ophthalmic, inhalation and oncology, because "returns had come down in the U.S. market compared to 5 years back"; projects were cut and the portfolio optimized.
• FY25 R&D budget: Expected between ₹550 cr to ₹600 cr, depending on project progress; R&D will grow in absolute amount next quarter and "marginally keep going up as the business grows."
• Capex winding down: No further brownfield or greenfield expansions; only maintenance capex and capacity debottlenecking within existing facilities, anticipated at "about INR300 crores" for FY25; no large capex on the R&D side either, only maintenance capex and equipment upgrades.
• Tax rate: Will continue under MAT at "around 17%."

API and Ex-U.S. Businesses

• API volume vs pricing: Slower offtake from some customers for a couple of quarters, but volume-wise the business looks good; volumes to regulated markets are strong, though there has been "some more pricing pressure in the market"; API remains a "very good margin business" and will continue growing on both volume and new products.
• API and formulation margins are separate: API price erosion does not benefit formulation gross margins because API is sold separately to regulated market customers; some API business is lumpy due to particular customers and lower offtake.
• Ex-U.S. growth trajectory: Over the last five years, the ex-U.S. business has grown at a 20% CAGR, and management expects that to continue; no guidance was given for FY25 specifically.

Guidance & Commitments

Key Metrics